Intraperitoneally injected Plasmodium has been shown to reduce MMP9 production by inhibiting IGF-1 signaling through the accumulation of hemozoin, thus inhibiting tumor angiogenesis in vivo (Wang et al., 2020). Here, MMP9 is linked to neoplasm.